MUMBAI: In a twist more fragrant than a bottle of sandalwood oil, Sharpline Broadcast Limited, a media player with an eye on diversification, has acquired a controlling 51 per cent stake in Unayur Marketing Private Limited—a company better known for ayurvedic elixirs than evening news. And yes, it’s a pivot. A juicy one.
On 3 April 2025, the company officially disclosed what had originally been approved way back on 11 February 2025: a Rs 9 crore deal to scoop up 5,123 equity shares in Unayur from shareholder Sahil Khan. Sharpline has now confirmed that the agreement will turn Unayur into a fully-fledged subsidiary, pending completion of standard conditions.
So what took so long to tell the world? A minor whoopsie in internal processes, apparently.
"While the intimation was duly signed on 11 February 2025, due to an inadvertent oversight... there was an unintended delay in uploading the same," the company said in a sheepish note to the BSE. The lapse was fixed on 31 March 2025, and the compliance machinery, we’re told, is now firmly greased.
So why Unayur? Because the herbal wellness train is on full throttle, and Sharpline wants a ticket.
The Delhi-based Unayur, incorporated in 2019, reported a turnover of Rs 66.30 crore in FY 2023-24. Its track record includes Rs 96.66 crore in FY 2022-23 and Rs 77.26 crore the year before that. The company deals in Unani and Ayurvedic medicines, herbal products, natural health goodies, essential oils, and is even eyeing clinics and hospitals for the holistic health crowd.
According to Sharpline, "The Company wants to diversify its current business and acquisition of a company with the desired business line is the best way to venture into the same."
None of the promoter group has any personal stake in Unayur beyond the acquisition, and no regulatory approvals are needed. The transaction is cash-only, with a one-month timeline to wrap it all up. A classic arm's-length deal, in every sense.
From digital screens to neem creams, Sharpline's strategy is now clearly shooting beyond the broadcast bandwidth. Will this cross-industry cocktail of content and capsules pay off?
Time, and perhaps turmeric, will tell.
